Best Miami Grants for Nonprofits in Florida

The Edna Mae Scholarship, offered by the Community Foundation of Southern New Mexico, aims to support women from rural communities in their pursuit of higher education at vocational community colleges or universities. This scholarship is open to applicants actively enrolled in any form of higher education, including undergraduate and vocational programs, with a special focus on assisting those in need. Applicants must be graduating high school seniors or currently enrolled students.

Betsy L. Bertoli Scholarship

Academic Focus:

• Accounting or business administration/management

Award Average:

• $250

For Torrington High School graduating seniors who plan to pursue a career in accounting or business administration/management at the university level and have had at least one successful high school semester of accounting.

The DoW Spinal Cord Injury Translational Research Award supports innovative research to transform promising spinal cord injury findings into clinical applications. It features an Early-Career Partnership Option, requiring at least one early-career principal investigator. Collaborations with SCI community partners are essential for providing guidance throughout the project. This funding opportunity aims to enhance the effectiveness of spinal cord injury interventions and improve patient outcomes.

The FY26 Spinal Cord Injury Research Program Clinical Translation Research Award funds innovative clinical research aimed at bridging the gap to larger clinical trials. It focuses on accelerating the application of new techniques and improving patient outcomes through effective diagnosis and rehabilitation strategies. Key features include an Early-Career Partnership Option for principal investigators and a requirement for community partner involvement, ensuring collaborative research that meets real-world needs.

The FY26 Spinal Cord Injury Research Program Clinical Trial Award supports innovative clinical trials aimed at significantly improving spinal cord injury treatment. This funding opportunity encourages collaboration by allowing two Principal Investigators, including an early-career investigator, to drive the research forward. Applicants must partner with at least two SCI community members, ensuring that the project is informed by lived experiences and community needs throughout its development and implementation.

The FY26 Spinal Cord Injury Research Program (SCIRP) Investigator-Initiated Research Award (IIRA) supports innovative research aimed at enhancing patient care and quality of life for individuals with spinal cord injuries. This award encourages collaboration, allowing an Early-Career Partnership Option for two Principal Investigators, where one must be an early-career investigator. Focused on impactful research from basic to translational science, this opportunity is crucial for advancing SCI knowledge and interventions.

The FY26 Melanoma Research Program Focused Program Award for Rare Melanomas supports multidisciplinary research initiatives aimed at addressing critical questions in rare melanomas. This award requires collaboration between an Initiating Principal Investigator and up to two Partnering PIs, with the inclusion of a rare melanoma survivor or patient advocate in the project team. Approximately $5.6M is allocated to fund two awards, each capped at $2.8M, over a maximum performance period of four years.

The Melanoma Research Program Melanoma Academy Scholar Award supports early career investigators within seven years of their initial faculty appointment. This unique virtual academy fosters collaboration among established researchers and Scholars, focusing on research and career potential in melanoma. With approximately $1.54M allocated to fund two Scholar Awards, each capped at $0.77M, the maximum performance period is three years, and funding is expected to be available until September 30, 2032.

The FY26 Melanoma Research Program Survivorship Research Award aims to enhance the well-being of melanoma survivors through innovative research. This funding opportunity supports studies that prioritize quality of life, involving melanoma survivors or their families as collaborators. With approximately $2.04M available, two awards of up to $1.02M each will be granted for research over a maximum period of three years. Applications must be submitted by September 30, 2027, to be funded with FY26 resources.

The FY26 Melanoma Research Program Idea Award encourages innovative and high-risk research to advance melanoma treatment. With a budget of approximately $5.6M for 10 awards, each grant can fund up to $0.56M over a maximum of 2 years. The program aims to support projects that establish proof of principle and generate preliminary data for future funding opportunities. Notably, preliminary data is discouraged, and applicants must receive an invitation to submit a full application after the pre-application stage.

The FY26 Pancreatic Cancer Research Program (PCARP) Idea Development Award promotes innovative, high-risk research aimed at significant advancements for pancreatic cancer outcomes. This award supports projects with preliminary data, focusing on impactful discoveries. It features a Partnering Principal Investigator option, enhancing funding for collaborations between experienced mentors and early-career researchers. All applications must align with the FY26 PCARP Focus Areas, ensuring relevance and potential for transformative results in pancreatic cancer research.

The FY26 Pancreatic Cancer Research Program (PCARP) Translational Research Partnership Award encourages collaboration among clinicians and scientists to expedite the clinical application of innovative pancreatic cancer research. A minimum of two Principal Investigators is required, with one designated as the Initiating PI. This award supports preliminary data collection and various research methodologies, excluding large-scale clinical trials, to enhance pancreatic cancer understanding and treatment.

The FY26 Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award supports innovative research aimed at advancing therapies for ALS. It focuses on projects that have demonstrated proof-of-concept efficacy and require lead compounds. The award emphasizes the development of mechanism-specific biomarkers to enhance trial design and patient selection, ensuring that therapeutic approaches are effective and efficient. Collaboration with experienced ALS researchers is encouraged for those with limited experience.

The FY26 Amyotrophic Lateral Sclerosis Research Program Therapeutic Idea Award supports innovative ideas for ALS drug discovery. This award encourages high-risk, high-gain research that is hypothesis-driven and aims to generate preliminary data for future therapeutic investigations. Applications should highlight potential impact and innovation, with the possibility of achieving results without prior data. The focus is on a strong approach rather than preliminary findings.

The FY26 DoW Pancreatic Cancer Research Program Focused Pilot Award aims to drive innovative and impactful research in pancreatic cancer, enhancing patient quality of life. This award encourages the development of preliminary data to support future clinical or real-world applications. While allowing for clinical research studies, it does not permit clinical trials or preclinical animal studies, ensuring a strong patient-centered approach in its research focus.

The FY26 Amyotrophic Lateral Sclerosis Research Program's Pilot Clinical Trial Award aims to accelerate clinical trials that can significantly impact ALS treatment and management. Focus areas include biomarker-driven interventions and improvements in clinical care. Trials must begin within 12 months of the award and incorporate community collaboration and a detailed regulatory strategy. This award emphasizes the importance of therapeutic interventions and a transition plan for advancing study outcomes beyond the funded work.

The FY26 Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) aims to enhance clinical trials for ALS by developing and validating clinical outcomes and biomarkers. This funding opportunity encourages innovative projects that may focus on specific therapies, ALS subtypes, or digital health measures. Collaboration with the ALS community is essential to ensure that research is relevant and informed by lived experiences.

The FY26 Breast Cancer Research Program (BCRP) Breakthrough Award Level 4 supports innovative research with the potential for significant breakthroughs in breast cancer. Applications must address key BCRP challenges or justify exceptions, focusing on impactful solutions. This program mandates clinical trials and requires participation from breast cancer consumer advocates. The funding supports single or partnered Principal Investigators, ensuring comprehensive submission processes to avoid administrative withdrawal.

The DoW Ovarian Cancer Academy Early-Career Investigator Award supports junior faculty in conducting innovative ovarian cancer research. Established in FY09, this unique virtual academy fosters mentorship, collaboration, and networking among Early-Career Investigators (ECIs) and their mentors. Participants engage in monthly webinars and annual workshops, enhancing their research skills while contributing to impactful studies in ovarian cancer. The program aims to cultivate a new generation of highly productive researchers in this critical field.

The Ovarian Cancer Clinical Trial Academy (OCCTA) supports Early-Career Investigators (ECIs) in clinical trial research aimed at effective ovarian cancer treatments. It provides essential mentoring, networking, and skill development needed for executing clinical trials. The FY26 funding will specifically support translational research and early-phase trials, requiring preliminary data and a commitment of at least 25% effort from the ECI. Mentorship is vital, with a focus on experienced clinical trialists guiding ECIs.

The DoW Ovarian Cancer Clinical Trial Award, funded by the U.S. Army Medical Command, aims to accelerate the implementation of clinical trials that significantly impact ovarian cancer treatment. This award supports diverse trial designs, from early proof-of-concept studies to large-scale efficacy trials, evaluating innovative drugs, biologics, and technologies. By fostering research in this critical area, the program seeks to enhance patient outcomes and advance the understanding of ovarian cancer management.

The FY26 Breast Cancer Research Program (BCRP) Breakthrough Award Level 3 supports transformative research aimed at significant advancements in breast cancer treatment. Applicants must address key challenges outlined by the program, ensuring their proposals demonstrate potential for impactful breakthroughs. This funding mechanism, which permits small-scale clinical trials, emphasizes collaboration by requiring research teams to include two breast cancer consumer advocates and allows for a single Principal Investigator or two partnering PIs.

The Ovarian Cancer Research Program (OCRP) Investigator-Initiated Research Award aims to support impactful research addressing critical needs in ovarian cancer and patient care. It requires a robust research plan with preliminary data and allows for studies across all research phases, excluding clinical trials. A unique Partnering Principal Investigator option encourages collaboration between two PIs to enhance research outcomes beyond individual efforts, promoting innovation in the field of ovarian cancer.

The DoW Ovarian Cancer Pilot Award fosters innovative research that challenges existing paradigms in ovarian cancer. It aims to propel groundbreaking discoveries and advancements in the field. Notably, the award prioritizes originality over scientific merit alone, ensuring that innovative ideas are at the forefront. The application process includes a blinded pre-application screening to maintain confidentiality and integrity, encouraging fresh perspectives in ovarian cancer research.

The FY26 Breast Cancer Research Program's Transformative Breast Cancer Consortium Award fosters significant collaborations that aim to revolutionize care for individuals affected by breast cancer. This award supports a multidisciplinary consortium of leading scientists, clinicians, and advocates to tackle major challenges in breast cancer research. Proposals must address at least one of the program's overarching challenges and demonstrate a transformative impact that cannot be achieved by individual investigators alone.

Geological Society of America 

The Geological Society of America (GSA), founded in 1888, is a global scientific society with members from academia, government, and industry in more than 100 countries. Through its meetings, publications, and programs, GSA enhances the professional growth of geoscientists at all career levels, encourages cooperative research among earth, life, planetary, and social scientists, fosters public dialogue on geoscience issues, and promotes the geosciences in the service of humankind. GSA is headquartered in Boulder, Colorado, USA.

Jack Kleinman Memorial Award for Volcano Research

The Jack Kleinman Memorial Award for Volcano Research represents a partnership between GSA and the U.S. Geological Survey (USGS) to recognize early-career scientists conducting high-impact research in volcanology. The award was created in memory of Jack Kleinman—a USGS Cascades Volcano Observatory scientist known for his commitment to collecting high-quality field data and who relished a challenge, inspired enthusiasm in others, and delighted in the natural world. The award honors students who demonstrate these same qualities in their scientific explorations.

Up to US$5,000 may be awarded to undergraduate, graduate, and aspiring graduate students, regardless of current enrollment status. Successful proposals typically focus on geologic, geochemical, geophysical, or hazards investigations with an emphasis on fieldwork. Cooperation with a staff member from the USGS Volcano Science Center is encouraged and given considerable weight in the selection process.

Funding is intended to defray the costs of field-focused studies, such as travel to field sites, living expenses during fieldwork, field supplies, and analytical costs. Awardees are invited to present their results in the USGS Kleinman Seminar Series and attend the Awards Ceremony at the GSA annual meeting.